Treating patients with schizophrenia deficit with erythropoietin?

Psychiatry and Clinical Neurosciences

Volumn 66, Issue 5, 2012, Pages 375-382

  Fond, Guillaume ^a,b,c   MacGregor, Alexandra ^a,b,c   Attal, Jérome ^a,b,c   Larue, Aurore ^a,b,c   Brittner, Marie ^a,b,c   Ducasse, Deborah ^a,b,c   Capdevielle, Delphine ^a,b,c  

^a UNIV MONTPELLIER   (France)

^b INSERM   (France)

^c Montpellier 1 University   (France)

Author keywords

cognition; erythropoietin; neuroprotection; oxydative stress; schizophrenia

Indexed keywords

DOPAMINE; ERYTHROPOIETIN; GLUTAMIC ACID; GLYCOPROTEIN P; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPROTECTIVE AGENT; TYROSINE 3 MONOOXYGENASE; VASCULOTROPIN;

ALZHEIMER DISEASE; AVERSION; BLOOD BRAIN BARRIER; BRAIN CORTEX; CELL VIABILITY; CHILD DEVELOPMENT; DNA DAMAGE; DOPAMINE RELEASE; ENZYME ACTIVITY; EXCITOTOXICITY; HIPPOCAMPUS; HUMAN; IMMUNOMODULATION; INFLAMMATION; LATENT PERIOD; LEARNING; MEMBRANE PERMEABILITY; MEMORY; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVOUS SYSTEM DEVELOPMENT; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

BLOOD-BRAIN BARRIER; COGNITION DISORDERS; ERYTHROPOIETIN; HUMANS; INFLAMMATION; NEUROGENESIS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; SCHIZOPHRENIA;

EID: 84864402810     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2012.02359.x     Document Type: Review

References (69)

1. Mikati MA, El Hokayem JA, El Sabban ME,. Effects of a single dose of erythropoietin on subsequent seizure susceptibility in rats exposed to acute hypoxia at P10. Epilepsia 2007; 48: 175-181. (Pubitemid 46096040)
2. Chong ZZ, Kang JQ, Maiese K,. Angiogenesis and plasticity: Role of erythropoietin in vascular systems. J. Hematother. Stem Cell Res. 2002; 11: 863-871. (Pubitemid 36139767)
3. Chong ZZ, Kang JQ, Maiese K,. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002; 106: 2973-2979. (Pubitemid 35424751)
4. Chong ZZ, Kang JQ, Maiese K,. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J. Cereb. Blood Flow Metab. 2002; 22: 503-514. (Pubitemid 34477771)
5. Chong ZZ, Kang JQ, Maiese K,. Erythropoietin: Cytoprotection in vascular and neuronal cells. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2003; 3: 141-154. (Pubitemid 36621798)
6. Chong ZZ, Kang JQ, Maiese K,. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br. J. Pharmacol. 2003; 138: 1107-1118. (Pubitemid 36459833)
7. Chong ZZ, Kang JQ, Maiese K,. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J. Cereb. Blood Flow Metab. 2003; 23: 320-330. (Pubitemid 36307576)
8. Chong ZZ, Maiese K,. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br. J. Pharmacol. 2007; 150: 839-850. (Pubitemid 46536625)
9. Moon C, Krawczyk M, Lakatta EG, Talan MI,. Therapeutic effectiveness of a single vs multiple doses of erythropoietin after experimental myocardial infarction in rats. Cardiovasc. Drugs Ther. 2006; 20: 245-251. (Pubitemid 44701158)
10. Moon C, Krawczyk M, Paik D, et al,. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J. Pharmacol. Exp. Ther. 2006; 316: 999-1005. (Pubitemid 43345271)
11. Maiese K, Chong ZZ, Li F, Shang YC,. Erythropoietin: Elucidating new cellular targets that broaden therapeutic strategies. Prog. Neurobiol. 2008; 85: 194-213.
12. Li F, Chong ZZ, Maiese K,. Erythropoietin on a tightrope: Balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 2004; 13: 265-289. (Pubitemid 40073625)
13. Tan CC, Eckardt KU, Firth JD, Ratcliffe PJ,. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am. J. Physiol. 1992; 263: F474-F481.
14. Bazan JF,. A novel family of growth factor receptors: A common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain. Biochem. Biophys. Res. Commun. 1989; 164: 788-795. (Pubitemid 19280337)
15. Watowich SS, Hilton DJ, Lodish HF,. Activation and inhibition of erythropoietin receptor function: Role of receptor dimerization. Mol. Cell. Biol. 1994; 14: 3535-3549. (Pubitemid 24160761)
16. Koshimura K, Murakami Y, Sohmiya M, Tanaka J, Kato Y,. Effects of erythropoietin on neuronal activity. J. Neurochem. 1999; 72: 2565-2572. (Pubitemid 29242209)
17. Maiese K, Li F, Chong ZZ,. New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-95. (Pubitemid 40066704)
18. Genc S, Koroglu TF, Genc K,. Erythropoietin and the nervous system. Brain Res. 2004; 1000: 19-31. (Pubitemid 38446486)
19. Maiese K, Hou J, Chong ZZ, Shang YC,. Erythropoietin, forkhead proteins, and oxidative injury: Biomarkers and biology. Sci. World J. 2009; 9: 1072-1104.
20. Maiese K, Li F, Chong ZZ,. Erythropoietin in the brain: Can the promise to protect be fulfilled? Trends Pharmacol. Sci. 2004; 25: 577-583. (Pubitemid 39371148)
21. Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M,. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J. Biol. Chem. 2001; 276: 39 469-39 475.
22. Blondeau N, Plamondon H, Richelme C, Heurteaux C, Lazdunski M,. K(ATP) channel openers, adenosine agonists and epileptic preconditioning are stress signals inducing hippocampal neuroprotection. Neuroscience 2000; 100: 465-474.
23. Siren AL, Fratelli M, Brines M, et al,. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl Acad. Sci. USA 2001; 98: 4044-4049. (Pubitemid 32249895)
24. Genc S, Koroglu TF, Genc K,. Erythropoietin as a novel neuroprotectant. Restor. Neurol. Neurosci. 2004; 22: 105-119. (Pubitemid 38850338)
25. Muller N, Riedel M, Hadjamu M, Schwarz MJ, Ackenheil M, Gruber R,. Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am. J. Psychiatry 1999; 156: 634-636. (Pubitemid 29162988)
26. Meyer U, Feldon J, Dammann O,. Schizophrenia and autism: Both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr. Res. 2011; 69: 26R-33R.
27. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E,. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007; 7: 46.
28. Baker I, Masserano J, Wyatt RJ,. Serum cytokine concentrations in patients with schizophrenia. Schizophr. Res. 1996; 20: 199-203. (Pubitemid 26387520)
29. Watanabe Y, Someya T, Nawa H,. Cytokine hypothesis of schizophrenia pathogenesis: Evidence from human studies and animal models. Psychiatry Clin. Neurosci. 2011; 64: 217-230.
30. Brines M, Cerami A,. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. 2005; 6: 484-494. (Pubitemid 40769173)
31. de Klerk OL, Willemsen AT, Bosker FJ, et al,. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: A PET study with [(11)C]verapamil as a probe for P-glycoprotein function. Psychiatry Res. 2010; 183: 151-156.
32. Bitanihirwe BK, Woo TU,. Oxidative stress in schizophrenia: An integrated approach. Neurosci. Biobehav. Rev. 2011; 35: 878-893.
33. Zhang M, Zhao Z, He L, Wan C,. A meta-analysis of oxidative stress markers in schizophrenia. Sci. China Life Sci. 2011; 53: 112-124.
34. Studer L, Csete M, Lee SH, et al,. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J. Neurosci. 2000; 20: 7377-7383.
35. Lee JY, Koh HC, Chang MY, Park CH, Lee YS, Lee SH,. Erythropoietin and bone morphogenetic protein 7 mediate ascorbate-induced dopaminergic differentiation from embryonic mesencephalic precursors. Neuroreport 2003; 14: 1401-1404. (Pubitemid 36936734)
36. Konishi Y, Chui DH, Hirose H, Kunishita T, Tabira T,. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res. 1993; 609: 29-35. (Pubitemid 23136796)
37. Toro CT, Deakin JF,. Adult neurogenesis and schizophrenia: A window on abnormal early brain development? Schizophr. Res. 2007; 90: 1-14. (Pubitemid 46177548)
38. Reif A, Schmitt A, Fritzen S, Lesch KP,. Neurogenesis and schizophrenia: Dividing neurons in a divided mind? Eur. Arch. Psychiatry Clin. Neurosci. 2007; 257: 290-299. (Pubitemid 47301407)
39. Ehrenreich H, Degner D, Meller J, et al,. Erythropoietin: A candidate compound for neuroprotection in schizophrenia. Mol. Psychiatry 2004; 9: 42-54. (Pubitemid 38175081)
40. Lipska BK, Weinberger DR,. To model a psychiatric disorder in animals: Schizophrenia as a reality test. Neuropsychopharmacology 2000; 23: 223-239. (Pubitemid 30609657)
41. Lieberman J, Chakos M, Wu H, et al,. Longitudinal study of brain morphology in first episode schizophrenia. Biol. Psychiatry 2001; 49: 487-499. (Pubitemid 32226407)
42. Bierer R, Peceny MC, Hartenberger CH, Ohls RK,. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 2006; 118: e635-e640. (Pubitemid 46089988)
43. Peng H, Derrick BE, Martinez JL Jr,. Identification of upregulated SCG10 mRNA expression associated with late-phase long-term potentiation in the rat hippocampal Schaffer-CA1 pathway in vivo. J. Neurosci. 2003; 23: 6617-6626. (Pubitemid 36909888)
44. Holahan M, Routtenberg A,. The protein kinase C phosphorylation site on GAP-43 differentially regulates information storage. Hippocampus 2008; 18: 1099-1102.
45. Solomonia RO, Apkhazava D, Nozadze M, Jackson AP, McCabe BJ, Horn G,. Different forms of MARCKS protein are involved in memory formation in the learning process of imprinting. Exp. Brain Res. 2008; 188: 323-330.
46. Tischmeyer W, Grimm R, Schicknick H, Brysch W, Schlingensiepen KH,. Sequence-specific impairment of learning by c-jun antisense oligonucleotides. Neuroreport 1994; 5: 1501-1504. (Pubitemid 24251882)
47. Arami S, Jucker M, Schachner M, Welzl H,. The effect of continuous intraventricular infusion of L1 and NCAM antibodies on spatial learning in rats. Behav. Brain Res. 1996; 81: 81-87. (Pubitemid 26384966)
48. Flashman LA, Green MF,. Review of cognition and brain structure in schizophrenia: Profiles, longitudinal course, and effects of treatment. Psychiatr. Clin. North Am. 2004; 27: 1-18. (Pubitemid 38367767)
49. Ehrenreich H, Hinze-Selch D, Stawicki S, et al,. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol. Psychiatry 2007; 12: 206-220. (Pubitemid 46160985)
50. Randolph C,. RBANS Manual: Repeatable Battery for the Assessment of Neuropsychological Status. 1998.
51. Heaton STKGIR. WCST-64: Wisconsin card sorting test-64 card version. 2000.
52. Kay SR, Fiszbein A, Opler LA,. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261-276. (Pubitemid 18039085)
53. Naber D, Moritz S, Lambert M, et al,. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr. Res. 2001; 50: 79-88. (Pubitemid 32510889)
54. Jung E, Biehl H, Maurer K, Bauer-Shubart C,. DAS-M disability assessment schedule. Beltz, Weinheim, 1989.
55. Kokhaei P, Abdalla AO, Hansson L, et al,. Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin. Cancer Res. 2007; 13: 3536-3544. (Pubitemid 46955113)
56. Hardee ME, Rabbani ZN, Arcasoy MO, et al,. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol. Cancer Ther. 2006; 5: 356-361.
57. Lai SY, Grandis JR,. Understanding the presence and function of erythropoietin receptors on cancer cells. J. Clin. Oncol. 2006; 24: 4675-4676. (Pubitemid 46630930)
58. Henke M, Laszig R, Rube C, et al,. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-1260. (Pubitemid 37324251)
59. Leyland-Jones B, Semiglazov V, Pawlicki M, et al,. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J. Clin. Oncol. 2005; 23: 5960-5972.
60. Baoutina A, Coldham T, Bains GS, Emslie KR,. Gene doping detection: Evaluation of approach for direct detection of gene transfer using erythropoietin as a model system. Gene Ther. 2007; 17: 1022-1032.
61. Diamanti-Kandarakis E, Konstantinopoulos PA, Papailiou J, Kandarakis SA, Andreopoulos A, Sykiotis GP,. Erythropoietin abuse and erythropoietin gene doping: Detection strategies in the genomic era. Sports Med. 2005; 35: 831-840. (Pubitemid 41464509)
62. Segura J, Pascual JA, Gutierrez-Gallego R,. Procedures for monitoring recombinant erythropoietin and analogues in doping control. Anal. Bioanal. Chem. 2007; 388: 1521-1529. (Pubitemid 47150877)
63. Kanbay M, Akcay A, Delibasi T, et al,. Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure. Adv. Ther. 2007; 24: 346-352. (Pubitemid 46988378)
64. Eliopoulos N, Gagnon RF, Francois M, Galipeau J,. Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. J. Am. Soc. Nephrol. 2006; 17: 1576-1584. (Pubitemid 43794660)
65. Orive G, De Castro M, Ponce S, et al,. Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules. Mol. Ther. 2005; 12: 283-289. (Pubitemid 41025098)
66. Yu YP, Xu QQ, Zhang Q, Zhang WP, Zhang LH, Wei EQ,. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci. Lett. 2005; 387: 5-10. (Pubitemid 41138199)
67. Montero M, Poulsen FR, Noraberg J, et al,. Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures. Exp. Neurol. 2007; 204: 106-117. (Pubitemid 46330263)
68. Erbayraktar S, Grasso G, Sfacteria A, et al,. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl Acad. Sci. USA 2003; 100: 6741-6746. (Pubitemid 36666650)
69. Maiese K, Chong ZZ, Shang YC,. Raves and risks for erythropoietin. Cytokine Growth Factor Rev. 2008; 19: 145-155.